Personalised approaches to reduce risks from Adverse Drug Reactions due to administration of multiple medications
- Terminas
- 2027-02-17
- Atidaryta
- 2026-10-29
- Biudžetas
- 341 600 000 €
- Tipas
- grant
Aprašymas
Expected Outcome:This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination “Ensuring equal access to innovative, sustainable, and high-quality healthcare”. To that end, proposals under this topic should aim to deliver results that are directed at, tailored towards and contributing to all the following expected outcomes:Patients benefit from decreased incidence of Adverse Drug Reactions (ADRs) caused by the administration of multiple medications (three or more medicinal products[1]) and enhanced health outcomes by ensuring safer and more effective use of medication.Healthcare professionals can adopt adverse drug reactions prevention and reduction strategies to integrate genetic and other biomarker information into clinical decision-making to optimise the use of medication, especially in situations of comorbidities.Healthcare systems benefit from cost savings thanks to reduced hospital admissions and other costs associated with ADRs related to the intake of multiple medicines.Clinical and regulatory guidelines and policies for medication management in case of multiple medications can be revised supported by robust evidence.Educational programs for healthcare providers and patients benefit from improved awareness and management of polypharmacy and ADRs. Scope:While medicinal products contribute considerably to the health of EU citizens, they can also have adverse reactions. It is estimated that around 5% of all h
Tinkamumas (iš šaltinio)
General conditions1. Admissibility Conditions, proposal page limit and layoutAdmissibility conditions are described in Annex A and Annex E of the Horizon Europe Work Programme General Annexes.Proposal page limits and layout are described in Part B of the Application Form available in the Submission System.2. Eligible CountriesEligible countries are described in Annex B of the Work Programme General Annexes.A number of non-EU/non-Associated Countries that are not automatically eligible for funding have made specific provisions for making funding available for their participants in Horizon Europe projects. See the information in the Horizon Europe Programme Guide.3. Other Eligibility ConditionsIn recognition of the opening of the US National Institutes of Health’s programmes to European researchers, any legal entity established in the United States of America is eligible to receive Union funding.If projects use satellite-based earth observation, positioning, navigation and/or related timing data and services, beneficiaries must make use of Copernicus and/or Galileo/EGNOS (other data and services may additionally be used).Subject to restrictions for the protection of European communication networks.Other eligibility conditions are described in Annex B of the Work Programme General Annexes.4. Financial and operational capacity and exclusionFinancial and operational capacity and exclusion are described in Annex C of the Work Programme General Annexes.5a. Evaluation and award: Award criteria, scoring and thresholdsAward criteria, scoring and thresholds are described in Annex D of the Work Programme General Annexes.5b. Evaluation and award: Submission and evaluation processesThe thresholds for each criterion will be 4 (Excellence), 4 (Impact) and 4 (Implementation). The cumulative threshold will be 12.Submission and evaluation processes are described in Annex F of the Work Programme General Annexes and the Online Manual.5c. Evaluation and award: Indicative timeline for evaluation and grant agreementIndicative timeline for evaluation and grant agreement are described in Annex F of the Work Programme General Annexes.6. Legal and financial set-up of the grantsThe granting authority may, up to 4 years after the end of the action, object to a transfer of ownership or to the exclusive licensing of results, as set out in the specific provision of Annex 5.Legal and financial set-up of the grants are described in Annex G of the Work Programme General Annexes.Specific conditions Specific conditions are described in the specific topic of the Work Programme. Application and evaluation forms and additional documents: Application and evaluation form templatesStandard application form (HE RIA, IA) - the application form specific to this call is available in the Submission SystemStandard evaluation form (HE RIA, IA) - will be used with the necessary adaptationsGuidanceHE Programme GuideModel Grant Agreement (MGA)HE MGACall-specific instructions Information on clinical
Ar šis kvietimas tinka jūsų organizacijai?
Nariams — automatinis tinkamumo vertinimas pagal jūsų profilį, raktažodžių paieška, filtrai, stebėjimo sąrašas ir pranešimai apie naujus panašius kvietimus.